In particular, we provide a foundation forfurther clinical research on the immunological treatment of endometriosis, possibly by targeting IL-33 or Tregs, or any other molecules in their interactive pathways, such as TGF-β1 or ST2. The gene discussed is IL33; the disease is endometriosis.